IXICO plc New contract in Huntington's disease (0234S)
September 28 2017 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 0234S
IXICO plc
28 September 2017
28(th) September 2017
IXICO plc
("IXICO" or the "Company")
New contract in Huntington's disease with US-based
pharmaceutical company
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announces that it has signed a new contract
with a customer for its technology enabled imaging services. The
contract value is US$690k over a two and a half year term.
This new contract is for a Phase II clinical trial evaluating
the safety and tolerability of a novel treatment for patients with
Huntington's disease. As part of the study, IXICO will use its
TrialTracker(TM) digital platform and scientific services to
provide a battery of advanced MRI imaging techniques and clinical
trial endpoints.
Giulio Cerroni, CEO of IXICO, commented
"We are delighted to announce this contract, building on our
successful track record as the partner of choice in Huntington's
disease clinical studies. This new contract further demonstrates
the value our customers see in IXICO's deep neurological disease
expertise combined with our proprietary digital technologies in
providing compliant data standardisation, collection and
analysis."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Tel: +44 20
Officer 3763 7499
Susan Lowther, Chief Financial Officer
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield /James 7408 4090
Wolfe
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTQDLFLDKFZBBX
(END) Dow Jones Newswires
September 28, 2017 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024